NCT05559008

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

A Umbrella Study in Relapsed/Refractory Peripheral T-cell Lymphoma Guided by Molecular Subtypes

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 116 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, prospective, open-label, interventional umbrella study to evaluate the efficacy and safety of targeted therapies guided by molecular subtypes in patients with relasped or refractory peripheral T-cell lymphoma.

Conditions

• Peripheral T Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Azacitidine Injection	Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
DRUG	Dasatinib	Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
DRUG	Linperlisib	Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes
DRUG	Tucidinostat	Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
DRUG	SHR2554	Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
DRUG	Camrelizumab	Camrelizumab and Apatinib will be administered in T3.2 subtypes
DRUG	Apatinib	Camrelizumab and Apatinib will be administered in T3.2 subtypes

Timeline

• Start date: 2022-09-30
• Primary completion: 2024-03-26
• Completion: 2026-01-26
• First posted: 2022-09-29
• Last updated: 2022-11-09

Locations

1 site across 1 country: China